GlycoMark (1,5-AG) Test
Hyperglycemia, Glycemic Variability, Beta-cell Function
Approved/CommercialActive
Key Facts
Indication
Hyperglycemia, Glycemic Variability, Beta-cell Function
Phase
Approved/Commercial
Status
Active
Company
About Precision Diabetes
Precision Diabetes, Inc., founded in 2018 and based in Raleigh, North Carolina, is a commercial-stage diagnostics company focused on diabetes. Its core asset is the exclusive global rights to the GlycoMark test, a biomarker for detecting recent hyperglycemia and glycemic variability. The company is building a portfolio of novel diagnostic tests and algorithms, leveraging partnerships to expand its offerings, with the goal of personalizing diabetes prevention, management, and treatment.
View full company profile